QVARCopy

• DRUGBANK - Beclomethasone
• indication:

  For the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older

• pharmacology:

• mechanism:

  Unbound corticosteroids cross cell membranes and bind with high affinity to specific cytoplasmic receptors. The result includes inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.

• toxicity:

  The acute toxicity of beclomethasone dipropionate is low. The only harmful effect that follows inhalation of large amounts of the drug over a short period of time is suppression of hypothalamic-pituitary-adrenal (HPA) function. Chronic: The excessive use of beclomethasone dipropionate over a long period could lead to adrenal suppression.

• absorprion:

  Mean peak plasma concentration was 88pg/ml at 0.5 hour

• halflife:

  2.8 hours

• roouteelimination:

  Irrespective of the route of administration (injection, oral or inhalation), BDP and its metabolites are mainly excreted in the feces. Less than 10% of the drug and its metabolites are excreted in the urine.

• volumedistribution:

• clearance: